Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs.

Trial Profile

Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 27 Apr 2018 Results of analysis of cognitive adverse events in NCT00866775 and NCT01091662 trials presented at the 70th Annual Meeting of the American Academy of Neurology
    • 27 Apr 2018 Results of analysis of the efficacy and tolerability of Eslicarbazepine Acetate by study period in NCT00866775 and NCT01091662 trials presented at the 70th Annual Meeting of the American Academy of Neurology
    • 27 Apr 2018 Results evaluating the frequency of psychiatric TEAEs using patient data from 093-045 and 093-046 trials presented at the 70th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top